skip to content »

Path-Immuno - Michael Ittman Laboratory

Houston, Texas

BCM faculty, staff and trainees are the heart of the organization.
Path-Immuno - Michael Ittman Laboratory
not shown on screen

Selected Publications

  • Giri, D. Ropiquet, F. and Ittmann, M. 1999. Alterations in expression of FGF2 and its receptor FGFR-1 in human prostate cancer. Clin. Canc. Res. 5: 1063-1071.
  • Ropiquet, F., Giri, D., Lamb, D., and Ittmann, M. 1999. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J. Urol. 162: 595-599.
  • Giri, D. and Ittmann, M. 2000. IL-1a is a paracrine inducer of FGF-7, a key epithelial growth factor in benign prostatic hyperplasia. Am. J. Pathol. 157: 249-255.
  • Ropiquet, F., Giri, D., Kwabi-Addo, B., Mansukhani, A., and Ittmann, M. 2000. Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. Cancer Res. 60: 4245-4250.
  • Ozen, M., Giri, D., Ropiquet, F., Mansukhani, A.,and Ittmann, M. 2001. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J. Natl. Canc. Instit. 93:1783-1790.
  • Castro, P., Giri, D., Lamb, D., and Ittmann, M. 2003. Cellular senescence in the pathogenesis of benign prostatic hyperplasia. The Prostate 55: 30-38.

E-mail this page to a friend